Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Resolvyx Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Resolvyx Pharmaceuticals is developing a new class of lipid mediators, dubbed resolvins, which are generated through the oxidation of the omega-3 fatty acids EPA and DHA. Although omega-3 fatty acids have long been heralded for their reputed ability to reduce inflammation, many grams of omega-3 fatty acids have to be consumed to produce any physiological effect. In contrast, Resolvyx says its resolvins are potent at low milligram quantities and so are good candidates for commercialization as drugs. Resolvyx is advancing two programs into the clinic.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts